| Published Version Download ( PDF | 4MB) | License: Creative Commons Attribution 4.0 |
Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo
Article
Cabrita, Ines, Kraus, Andre, Scholz, Julia Katharina, Skoczynski, Kathrin, Schreiber, Rainer, Kunzelmann, Karl
and Buchholz, Björn
(2020)
Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo.
Nature Communications 11, p. 4320.
DOI to cite this document: 10.5283/epub.44976
Abstract
In autosomal dominant polycystic kidney disease (ADPKD) multiple bilateral renal cysts gradually enlarge, leading to a decline in renal function. Transepithelial chloride secretion through cystic fibrosis transmembrane conductance regulator (CFTR) and TMEM16A (anoctamin 1) are known to drive cyst enlargement. Here we demonstrate that loss of Pkd1 increased expression of TMEM16A and CFTR and Cl- ...
In autosomal dominant polycystic kidney disease (ADPKD) multiple bilateral renal cysts gradually enlarge, leading to a decline in renal function. Transepithelial chloride secretion through cystic fibrosis transmembrane conductance regulator (CFTR) and TMEM16A (anoctamin 1) are known to drive cyst enlargement. Here we demonstrate that loss of Pkd1 increased expression of TMEM16A and CFTR and Cl- secretion in murine kidneys, with TMEM16A essentially contributing to cyst growth. Upregulated TMEM16A enhanced intracellular Ca2+ signaling and proliferation of Pkd1-deficient renal epithelial cells. In contrast, increase in Ca2+ signaling, cell proliferation and CFTR expression was not observed in Pkd1/Tmem16a double knockout mice. Knockout of Tmeml6a or inhibition of TMEM16A in vivo by the FDA-approved drugs niclosamide and benzbromarone, as well as the TMEM16A-specific inhibitor Ani9 largely reduced cyst enlargement and abnormal cyst cell proliferation. The present data establish a therapeutic concept for the treatment of ADPKD.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Nature Communications | ||||
| Publisher | Nature | ||||
| Open Access Type | DEAL (Springer Gold) | ||||
| Place of Publication | BERLIN | ||||
| Volume | 11 | ||||
| Page Range | p. 4320 | ||||
| Date | 28 August 2020 | ||||
| Date of publication | 19 Feb 2021 09:48 | ||||
| Institutions | Biology, Preclinical Medicine > Institut für Physiologie > Prof. Dr. Karl Kunzelmann | ||||
| Identification Number |
| ||||
| Keywords | KIDNEY-DISEASE; ANO1; CFTR; SECRETION; PROLIFERATION; ACTIVATION; EXPRESSION; | ||||
| Dewey Decimal Classification | 500 Science > 570 Life sciences | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| URN of the UB Regensburg | urn:nbn:de:bvb:355-epub-449769 | ||||
| Item ID | 44976 |
Download Statistics
Download Statistics